Canada markets close in 30 minutes

Applied Therapeutics, Inc. (APLT)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.9527-0.1673 (-14.94%)
As of 03:27PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close1.1200
Bid0.9500 x 1000
Ask0.9650 x 1000
Day's Range0.8750 - 0.9681
52 Week Range0.5000 - 11.4700
Avg. Volume352,027
Market Cap45.786M
Beta (5Y Monthly)1.52
PE Ratio (TTM)N/A
EPS (TTM)-4.0020
Earnings DateNov 09, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.50
  • GlobeNewswire

    Applied Therapeutics Reports Third Quarter 2022 Financial Results

    NEW YORK, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today reported financial results for the third quarter ended September 30, 2022. “In the third quarter, we made significant progress across all three of our late-stage programs,” said Shoshana Shendelman, PhD, Founder, CEO and C

  • GlobeNewswire

    Applied Therapeutics Announces Multiple Data Presentations at the American Heart Association Scientific Sessions November 5-7, 2022

    Additional preclinical data supports AT-001 as an effective treatment for Diabetic Cardiomyopathy, reducing cardiac fibrosis and adverse remodelingBaseline analysis of Phase 3 ARISE-HF study supports the primary endpoint (cardiac functional capacity as measured by Peak VO2) as an important metric of quality of life and physical functioning in Diabetic Cardiomyopathy patients NEW YORK, Oct. 31, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical

  • GlobeNewswire

    Applied Therapeutics Announces Full Enrollment in the Registrational Phase 3 ARISE-HF Trial of AT-001 in Diabetic Cardiomyopathy

    ARISE-HF is a global registrational study in 675 patients with Diabetic Cardiomyopathy (DbCM), evaluating the potential of AT-001 to improve or prevent worsening of cardiac function vs. placeboPrimary study endpoint is cardiac functional capacity (measured by Peak VO2) at 15 monthsDbCM is a form of heart failure affecting approximately 20% of Type 2 Diabetes patients (~6M patients in the US and ~5M in EU), which represents a significant commercial market opportunityThere are currently no treatme